Two bottles sit on a kitchen counter in Mabushi. One is a tall slim can of an imported energy drink that the man of the house has been buying by the carton from the supermarket on Aminu Kano Crescent for the last six years. The other is a brown 75 cl bottle of locally bottled herbal bitters — agbo, in the loose Yoruba sense the seller at the junction uses — that his mother started bringing him when his blood pressure first edged into the hypertensive range. He is fifty-two, a project manager at a construction firm, on a borderline antihypertensive regimen he sometimes forgets to take. He drinks two of the cans most evenings to make it through the after-five workload. He pours a small cup of the bitters on Sunday mornings because it is what his mother does. He does not think of either bottle as medicine. He thinks of them as habits.
In about a year, his file will be the one a nephrologist opens on a Wednesday afternoon and closes with the words we are too late.
This is the second piece in a short series about the silent epidemics that default Nigerian care does not catch in the men who walk past it. The first was about erectile dysfunction as the cardiovascular warning most men self-medicate past. This one is about what happens when the next signal — the kidney enzymes, the liver function tests, the urinary protein — is also being received, also being ignored, and is being actively accelerated by what the patient is voluntarily ingesting on a Tuesday and a Sunday.
The clinical reality nobody outside nephrology talks about
Nigeria has, by the most generous available estimates, somewhere on the order of one nephrologist per one million people. Comparable developed-world figures sit at twenty or more per million. Domestic dialysis capacity is sparse, geographically concentrated in Lagos, Abuja, and Ibadan, and priced in a way that puts sustained treatment out of reach for almost everyone who needs it — a single session is typically ₦80,000 to ₦200,000, and chronic kidney failure requires two or three of those sessions every week, indefinitely. Renal transplantation domestically is rare, the waiting list is functionally non-existent, and the donor and post-operative immunosuppression infrastructure is not where it needs to be to make transplant a realistic standard of care. Liver transplant capacity in Nigeria, for practical purposes in 2026, does not yet exist at scale.
What this means in plain language is that end-stage kidney disease or end-stage liver disease in a Nigerian man, outside the small population that can credibly fly out and pay foreign retail, is a death sentence with a calendar attached to it. There is no good late-stage option. The entire game has to be played in the early stages — where biochemistry is drifting but symptoms are silent, where a creatinine that has crept from 89 to 124 to 162 over three annual physicals is the only warning the body sends. Default care almost never catches that drift, because default care does not run those tests serially, and the patient does not come for them.
That is the system into which the two bottles on the Mabushi counter are pouring their respective contents.
The first bottle — energy drinks, the liver, and the masked drinker
Modern energy drinks contain caffeine doses that have moved a long way from where this category started. A typical can sold in Nigerian supermarkets and roadside fridges delivers somewhere between 160 and 300 milligrams of caffeine — roughly two to three cups of strong coffee in a single sitting, swallowed cold in under two minutes. The same can usually contains taurine in gram quantities, niacin frequently at multiples of the recommended daily intake, sugar at 25 to 40 grams per serving, and a rotating cast of herbal extracts that may or may not be on the label depending on the importer and the batch.
Three things go wrong with this, and they go wrong in combination.
The first is direct hepatotoxicity from high-dose niacin. Acute liver injury from energy drink consumption is documented in the international medical literature in case-report form, with the niacin load consistently fingered as the most likely active agent in the cases where the patient's only chronic exposure was the drinks themselves. These reports describe young, otherwise healthy men presenting with jaundice, derangement on the liver-function panel, and on biopsy the histological pattern of drug-induced hepatitis. Most recover when the exposure stops. Some do not.
The second is the slow-burn of non-alcoholic fatty liver disease driven by the chronic sugar load. The Nigerian man drinking two cans an evening, six evenings a week, is consuming somewhere between 300 and 500 grams of added sugar a week from those cans alone — independently of the rest of his diet. Fructose and sucrose at that intake, in a man who is sedentary at his desk job and possibly already pre-diabetic, is the classic exposure for NAFLD progression. NAFLD progresses silently. By the time it is named NASH and then cirrhosis, the patient is in his fifties, his liver-function tests are off, and the conversation he gets to have with his hepatologist is about damage that has already happened.
The third is the masked-drinker problem. In the Nigerian club, on the construction site, and at the corporate-event after-party, energy drinks are very frequently mixed with spirits — the Red Bull and vodka, the Power Horse and brandy, the Monster and cognac. The caffeine in the drink hides the sedating effect of the alcohol. The drinker, who would normally notice he was approaching his tolerance and slow down, does not notice. He keeps drinking past it. He drinks longer, drinks more, and ingests a quantity of alcohol he genuinely would not have ingested without the caffeine in his bloodstream. The liver bill for that is the additive sum of the energy drink and the alcohol, and the liver does not differentiate between the two on the way to fibrosis.
The combined cultural script under all three is the same. The script is more. More stamina, more focus, more virility, more output. The bottle is consumed as performance enhancement. The damage it does is not seen as a cost of the performance because the performance feels real, and the damage is silent until it isn't.
The second bottle — agbo, the kidneys, and the false framing of "natural"
The herbal medicine tradition in Nigeria is older, deeper, and more legitimately part of the country's medical history than any criticism of it ought to forget. Agbo, in its true sense, is a category of decoctions and infusions assembled by a knowledgeable preparer for a specific person and a specific condition. That tradition is real, and a respectful critique of its industrialised modern form has to start by not pretending the tradition itself is the problem.
The problem is what happens when the tradition is industrialised, bottled, sold by the carton in junction shops and online marketplaces, mass-produced by people who are not herbalists for buyers who do not know the herbalist, and consumed weekly for years by patients who do not have the underlying condition the original preparation was designed for. That is not the tradition. That is a different product altogether, sold under the tradition's name, and it is the product most Nigerian men are drinking.
The harm vectors at that scale are well characterised.
Aristolochic acid nephropathy is the most decisive. Aristolochia species — present in multiple West African and Asian traditional preparations marketed for weight loss, "blood cleansing," fertility, and joint pain — contain compounds that cause irreversible interstitial fibrosis of the kidneys and a documented increase in urothelial cancer years later. The pathology has been mapped well enough that aristolochic acid is now a banned ingredient in the European Union, the United States, Japan, and Taiwan. It is not effectively regulated in Nigeria. The patient drinking the preparation has no way of knowing whether the bottle in front of him contains it.
Heavy metal contamination is the second. Lead, cadmium, mercury, and arsenic at concentrations above WHO safe limits have been documented in samples of Nigerian herbal preparations by laboratories at Lagos and Ibadan teaching hospitals — sometimes from intentional addition, more often from contaminated raw plant sources and poorly controlled processing. Chronic low-dose exposure scars the kidneys over years and produces a clinical picture in middle age that is indistinguishable from hypertensive nephropathy. The patient and the doctor blame the blood pressure. The metals quietly continue their work.
Adulteration with undisclosed pharmaceutical agents is the third, and it is the one most likely to be missed by the patient. The same problem we flagged in the previous piece about counterfeit ED drugs is at work in this market in a different category. Herbal preparations marketed for joint pain or arthritis have been found to contain diclofenac, ibuprofen, or other non-steroidal anti-inflammatories at clinically meaningful doses — chronic NSAID use being one of the most reliable ways to destroy kidneys in middle age. Herbal preparations for diabetes have been found to contain glibenclamide or other sulfonylureas, capable of causing severe hypoglycaemia in a patient who does not know he is taking them. Herbal preparations for "hypertension" have been found to contain hydrochlorothiazide. The patient is being prescribed a real pharmaceutical agent by a person who is not a pharmacist, at a dose nobody has calculated, with no monitoring, while believing he is drinking tea.
The cultural script under all of this is the inverse of the energy-drink script. The script for the bitters bottle is pure. Gentler, more natural, less foreign than the white doctor's pill, more aligned with the body, less industrial. That script is, in the specific case of the industrialised modern agbo market in Nigeria, demonstrably false. The product on the supermarket shelf bears a real and legitimate cultural name. The contents are something else.
Why these specifically attack Nigerian men
The man on the Mabushi kitchen counter is not a special case. He is the modal case. The same demographic that carries the hypertension and diabetes load this country is now running on — men in their forties and fifties, with high stress, sedentary jobs, borderline metabolic control, and limited interaction with a continuous physician — is also the demographic doing most of the energy-drink consumption and most of the agbo consumption.
Each exposure on its own is harmful. The combination is worse than the sum, for three reasons.
The hypertensive kidney is already under pressure. Adding aristolochic acid, heavy metals, or chronic occult NSAIDs to a kidney already trying to absorb the strain of poorly controlled blood pressure shortens the timeline. The patient does not present with kidney symptoms until the GFR is in the thirties. By then the damage is done.
The pre-diabetic liver is already vulnerable. Adding the chronic sugar load and intermittent alcohol of the energy-drink axis to a liver already trending toward fatty change shortens the timeline. The patient does not present with liver symptoms until the LFTs are obviously deranged. By then the damage is done.
The healthcare system can absorb neither outcome. Each end-stage patient becomes a question — dialysis or not, transplant or not, foreign or not — with no good answer for almost any Nigerian household. Which means the only winnable version of the game is to catch the drift early, while it can still be acted on, and while the patient still has something to protect.
What gets lost when the conversation does not happen
The signal kidneys and livers send is not pain. The signal is biochemistry. A serum creatinine drifting from 89 to 124 to 162 over three annual physicals. An ALT trending from the low thirties into the seventies. An albumin-creatinine ratio that has gone from negative to mildly positive. An eGFR that was 95 and is now 71. None of these produce symptoms. All of them are clinically actionable.
Default Nigerian primary care does not run them serially, because the patient does not return to the same doctor often enough for serial comparison to be possible. The result is that every physical the man has is a snapshot, scored against population reference ranges that are too broad to catch a trend in any one person. By the time the value crosses out of the reference range entirely, the trend has been there for years and the damage has been accumulating along the trend.
What is lost, exactly, in the missed conversation is this. The man with the two bottles on his Mabushi counter is, in year one, healthy on paper but trending. In year three, he is still healthy on paper but trending faster — and in this year, an honest annual physical with biochemistry read against last year's baseline would have flagged it, and a physician who knew him well enough to ask what was actually in the cupboard would have got an honest answer. The damage at year three is reversible. By year five it is not. Year five is when his GP, who he sees twice that year and who is not the same GP either time, decides his blood pressure is the problem. By year seven he is in front of a nephrologist for the first time. By year eight the conversation is the wrong conversation, because the right one was two years and three years and four years ago.
What concierge medicine catches
A serious annual physical contains, at minimum, a comprehensive metabolic panel, a full liver-function panel, a fasting lipid profile, an HbA1c, a urinalysis, an albumin-creatinine ratio, and an eGFR. Most senior Nigerian executives have never had all of those done in the same year. Almost none of them have had them done serially, against their own prior values, with a physician who has read both years' results in sequence.
That serial reading is the point. Population reference ranges are too broad to catch a single patient's trend. Year-on-year comparison against the patient's own baseline is what catches the drift. A creatinine that has gone from 89 to 124 over three years is still inside the population reference range. It is still also, in that specific man, the beginning of something. The physician who notices is the physician who has the prior values, and who has the relationship to ask, candidly, what he has been drinking that he is not yet calling drinking.
The harder ask, and the one the relationship has to earn, is the honest disclosure. The man who comes in for his annual review will tell you about the antihypertensive he is taking. He will not tell you, unprompted, about the four cans of Power Horse a week or the Sunday-morning bitters. Both of those have to be drawn out — without judgement, in a setting designed for the conversation not to feel like a confession. The energy drinks are usually disclosed in the first conversation if asked plainly. The agbo, like the erectile dysfunction in the previous piece, is usually disclosed when the relationship has earned it.
Where the drift is caught early, the play is straightforward. Stop the exposure. Tighten the antihypertensive control. Tighten the glycaemic control. Reassess in three months, not in a year. Where the damage is already advanced, the play is honest. A candid conversation about what can still be salvaged, what the trajectory looks like without further intervention, and what the renal or hepatology referral pathway is for the specific damage the patient already carries. Neither of those conversations happens at the junction shop, and neither happens in a primary-care visit that lasts seven minutes with a doctor who is meeting the patient for the first time.
Closing
The Nigerian conversation about herbal medicine and energy drinks is bad-faith on every side. The biomedical establishment dismisses agbo as superstition. The herbal sellers claim everything in their bottles is safe because it is natural. The energy-drink manufacturers point at international approvals and decline to publish full ingredient panels. The patient, caught between three parties none of whom is telling him the truth, makes a guess in the supermarket aisle and lives with the consequences in a kidney clinic he cannot afford fifteen years later.
There is a better version of the conversation. It acknowledges that traditional medicine has real value, and that the industrialised modern bottled-and-branded version of it on the supermarket shelf is a different product altogether, frequently adulterated, frequently contaminated, and frequently dangerous in ways the buyer cannot detect. It acknowledges that energy drinks are not coffee, and that the cumulative metabolic and hepatic load of drinking them daily for a decade is not free. And it acknowledges that the only winnable version of the kidney and liver game in Nigeria, given the infrastructure available, is the version played early — at the trend stage, with serial biochemistry, in the office of a physician who knows the patient and is allowed to ask awkward questions.
That conversation is what concierge medicine, properly built, is for. The first hour is private and costs nothing.